Should You Forget Altria? Why You Might Want to Buy This Unstoppable High-Yield Dividend Growth Stock Instead.

Altria faces structurally declining cigarette volumes—down 10.6% through the first nine months of 2025 following 10.2% in 2024 and 9.9% in 2023—while cigarettes comprise ~89% of sales, 97% of smokables volume, and Marlboro ~85% of overall volume; the company relies on price increases and buybacks to support a 6.9% yield, which the author flags as risky. By contrast, Clorox (4.5% yield) is executing a turnaround after pandemic-related demand weakness and a hacking disruption, with gross margin recovering from 33% in Q2 2023 to 41.7% in fiscal Q1 2026 and a 48-year streak of dividend increases, making it the preferred dividend-growth alternative for income-focused investors.

Analysis

Market structure: Winners are branded, innovation-led staples like CLX which can expand shelf share and pricing power as consumers trade up to trusted, differentiated SKUs; losers are legacy cigarette makers (MO) facing structural volume declines ~10% y/y with concentrated brand risk (Marlboro ~85% volume). Pricing power for MO has masked erosion via raises and buybacks; that lever is finite and increases equity risk and credit spread sensitivity for high-yield names. Cross-asset: rising perceived credit/default risk in tobacco could push MO bond spreads +100–200bp in a stress scenario, lift equity implied volatility, and make high-yield bond funds more volatile; commodities and FX impact is minimal.

Risk assessment: Tail risks include regulatory action (flavor bans, excise hikes) that could produce 15–30% EPS downside for MO over 12–24 months, major litigation or another cyberattack for CLX that could compress gross margins 200–500 bps. Time horizons: immediate (days) event-driven moves on headlines; short-term (3–9 months) earnings/margin normalization for CLX; long-term (2–5 years) secular decline for cigarettes. Hidden dependencies: MO’s dividend sustainability depends on buyback cadence and regulatory/legal outcomes; second-order effects include retailer consolidation changing shelf dynamics.

Trade implications: Direct plays: long CLX (fundamentals + yield) and short MO (structural decline). Use pair trades to hedge market beta (long CLX / short MO sized by beta-adjusted notional). Options: buy 9–12 month CLX LEAPs or buy-and-write; for MO use 6–12 month put spreads to express asymmetric downside. Sector rotation: reduce pure tobacco exposure, reallocate to high-ROIC staples (CLX, PG, KMB) over 6–24 months.

Contrarian angles: Consensus may overstate immediacy of MO’s collapse — Altria’s cash flow and pricing could sustain dividend 12–24 months absent regulatory shocks, creating tactical short-term downside limits. Conversely CLX’s recovery may be underpriced if margins hold >40% and innovation drives 2–4% organic growth — upside of 20–35% over 12–24 months if multiples re-rate. Monitor catalysts closely to avoid crowding in yield-chasing trades and miss regulatory regime shifts.

Key Decisions for Investors

• Establish a 1.5–3.0% portfolio long position in CLX (NYSE: CLX) using either outright shares or 9–12 month LEAPs; prefer entry if forward P/E ≤16 or dividend yield ≥4.2%; target hold 12–24 months and consider selling 1–2 near-term covered calls to enhance yield.
• Establish a 1.0–2.0% portfolio short exposure to MO (NYSE: MO) via 6–12 month put spreads (buy 30–40% OTM, sell deeper OTM to fund) or modest outright short if able; unwind if MO credit spreads widen >150bp or cigarette volume decline slows to <5% y/y.
• Implement a pair trade: long CLX and short MO with beta-adjusted sizing (dollar-neutral by 3–6 month beta) to isolate idiosyncratic staples vs tobacco thesis; rebalance monthly and close after 12–18 months or on material regulatory headlines.
• Hedge tail risk: buy 12-month MO protective puts sized to 1% portfolio if regulatory probability (e.g., announced federal excise increase or flavor ban) exceeds 30% within 90 days; alternatively rotate 3–5% of tobacco exposure into PG/KMB to lower single-name risk.